What is the terminal half-life of the drug?

The terminal half-life is 68 hours.

Is the production line GMP approved?

Yes, the production lines are GMP approved with full automation control.

What are the payment terms?

Payment terms include LC and T/T.

Azithromycin Tablet 250mg GMP Plant

Name: Azithromycin Tablet 250mg GMP Plant
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 1921604552

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.01-0.10

100,000 Pieces

Sample price:US$0.10/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

For oral administration

Model NO.

250mg

Suitable for

Elderly, Adult

State

Solid

Shape

Tablet

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Production Line

GMP Approved

Transport Package

Carton

Specification

250mg

Trademark

SHIMEN

Origin

Hebei

HS Code

3004909099

Production Capacity

1000000

Key features

GMP Approved Production: Manufactured in a GMP approved plant with full automation control.

Antibiotic Action: Macrolide antibiotic derived from erythromycin inhibiting protein synthesis.

Rapid Absorption: Rapidly absorbed with time to reach maximum concentration at 2.2 hours.

Wide Distribution: Distributed widely throughout the body with 68-hour terminal half-life.

Oral Administration: Designed specifically for oral administration as a dispersable tablet.

Suitable for Adults: Formulated for use by adults and elderly patients.

Global Export: Exported to over 80 countries across Asia, Americas, Europe, and Africa.

70-Year History: Manufacturer with a seventy-year business history in the pharmaceutical industry.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤18hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.